


17. The use of a 1H-indazole-3-carboxamide according to claim 16, wherein said bipolar disorders are selected from the group consisting of bipolar I, bipolar II, cyclothymia and bipolar disorder not otherwise specified (BD-NOS).
- 5 18. The use of a 1H-indazole-3-carboxamide according to claim 16, wherein said depressive disorders are selected from the group consisting of major depressive disorder (MDD), atypical depression (AD), melancholic depression, psychotic major depression (PMD), catatonic depression, postpartum depression (PPD), seasonal  
10 affective disorder (SAD), dysthymia, and depressive disorder not otherwise specified (DD-NOS).
19. The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said substance abuse disorders are selected from the group of abuse disorders due to psychostimulants.
- 15 20. The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said schizophrenic disorders are selected from the group consisting of paranoid schizophrenia, disorganized schizophrenia, catatonic schizophrenia, simple schizophrenia, residual schizophrenia, and undifferentiated schizophrenia.
- 20 21. The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said cancerous disorders are selected from the group consisting of prostate, pancreatic, ovarian, and colon-rectal cancer and MLL-associated leukaemia.
- ~~22. A method of treatment of a pathological state arising from the~~  
25 ~~uncontrolled activation and/or over expression of GSK 3 $\beta$ , selected from the group consisting of (i) insulin resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain, by the~~  
30 ~~administration to a human being in need thereof of an effective amount of a 1H-indazole-3-carboxamide having the following general formula (I):~~

66



~~wherein~~

~~R<sub>a</sub> and R<sub>a'</sub>, equal or different each other, is a hydrogen atom; a halogen atom; a hydroxy group; a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl and C<sub>1</sub>-C<sub>6</sub> alkoxy group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, NH<sub>2</sub>, and C<sub>1</sub>-C<sub>3</sub> alkoxy; a carbocyclic or heterocyclic ring, aliphatic or aromatic, having from 3 to 12 members, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, -NR<sub>1</sub>R<sub>2</sub>, -C(O)OH, C(O)OR<sub>1</sub> and -C(O)NR<sub>1</sub>R<sub>2</sub>,~~

~~Y is a bond, a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl or C<sub>2</sub>-C<sub>6</sub> alkynyl group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, NH<sub>2</sub>, and C<sub>1</sub>-C<sub>3</sub> alkoxy;~~

~~R<sub>b</sub> is a C<sub>1</sub>-C<sub>6</sub> alkoxy group; C(O)OH; C(O)OR<sub>1</sub>; NO<sub>2</sub>; NHG(O)R<sub>1</sub>; R<sub>1</sub> and R<sub>2</sub> are independently a hydrogen atom, a C<sub>1</sub>-C<sub>4</sub> alkyl group, a C<sub>2</sub>-C<sub>4</sub> alkenyl group, a C<sub>2</sub>-C<sub>4</sub> alkynyl group, and a phenyl group; and its salts of addition with pharmaceutically acceptable organic and inorganic acids and bases;~~

- 20 ~~23~~. A pharmaceutical composition comprising an effective amount of at least one compound of formula (I) as defined in any one of claims 1-11 above, a salt thereof with a pharmaceutically acceptable organic or inorganic acid or base, ~~or a prodrug thereof~~, and at least one inert pharmaceutically acceptable excipient.

25

17. The use of a 1H-indazole-3-carboxamide according to claim 16, wherein said bipolar disorders are selected from the group consisting of bipolar I, bipolar II, cyclothymia and bipolar disorder not otherwise specified (BD-NOS).
- 5 18. The use of a 1H-indazole-3-carboxamide according to claim 16, wherein said depressive disorders are selected from the group consisting of major depressive disorder (MDD), atypical depression (AD), melancholic depression, psychotic major depression (PMD), catatonic depression, postpartum depression (PPD), seasonal  
10 affective disorder (SAD), dysthymia, and depressive disorder not otherwise specified (DD-NOS).
19. The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said substance abuse disorders are selected from the group of abuse disorders due to psychostimulants.
- 15 20. The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said schizophrenic disorders are selected from the group consisting of paranoid schizophrenia, disorganized schizophrenia, catatonic schizophrenia, simple schizophrenia, residual schizophrenia, and undifferentiated schizophrenia.
- 20 21. The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said cancerous disorders are selected from the group consisting of prostate, pancreatic, ovarian, and colon-rectal cancer and MLL-associated leukaemia.
- 25 22. A pharmaceutical composition comprising an effective amount of at least one compound of formula (I) as defined in anyone of claims 1-11 above, a salt thereof with a pharmaceutically acceptable organic or inorganic acid or base and at least one inert pharmaceutically acceptable excipient.